🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
1,930

Quick answer

1,930 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 12329739

    Isoflavonoid compounds and methods for the treatment of cancer

    Aardvark Therapeutics, Inc. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12325691

    Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain

    The Board of Regents of the University of Texas System · Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12325755

    Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics

    The Regents of the University of California · Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12325854

    Crispr-CPF1-related methods, compositions and components for cancer immunotherapy

    Editas Medicine, Inc. · Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12325705

    Small molecules for the treatment of primary cancer and cancer metastasis

    The Board of Regents of the University of Texas System · Granted Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12319738

    Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer

    Five Prime Therapeutics, Inc. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12318386

    Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer

    Karyopharm Therapeutics Inc. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12318364

    Isoflavonoid compositions and methods for the treatment of cancer

    Aardvark Therapeutics, Inc. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12318401

    Injectable shear-thinning hydrogel containing therapeutic agent for enhanced tumor therapy

    The Regents of the University of California · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12311017

    Identification of immunologically protective neo-epitopes for the treatment of cancers

    UNIVERSITY OF CONNECTICUT · Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12310986

    Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxidative stress

    The Board of Regents of the University of Texas System · Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12310965

    Treatment of cancer utilizing an identified adenosine fingerprint

    Arcus Biosciences, Inc. · Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12303724

    Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer

    Takeda Pharmaceutical Company Limited · Granted Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12297509

    Biomarkers for predicting tumor response to and toxicity of immunotherapy

    MIRA DX, INC. · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12291502

    Topoisomerase II-alpha inhibitors and methods of treating cancer using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12291559

    Compositions and methods for treating cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12290551

    Methods for imaging and treatment of somatostatin-receptor positive tumors

    Corcept Therapeutics Incorporated · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12285425

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12285473

    Cancer vaccines targeting MUC16 and uses thereof

    Inovio Pharmaceuticals, Inc. · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12286483

    Method of treating cancer using CD137 antibodies and PD-1 antagonists

    Compass Therapeutics LLC · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12280120

    Tumor-specific cleavable linkers

    Xilio Development, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12280159

    Therapeutic protein-based nanoparticles for treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12281079

    Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer

    Lead Discovery Center GmbH · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12281310

    Use of trinucleotide repeat RNAs to treat cancer

    Northwestern University · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12280140

    Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12275685

    Oligo-benzamide analogs and their use in cancer treatment

    The Board of Regents of the University of Texas System · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12274735

    IL-4-fusion formulations for treatment of central nervous system (CNS) tumors

    Medicenna Therapeutics Inc. · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12263173

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12263169

    Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12263143

    Ionic channel modulation as a method for treating tumors through inflammasome activation

    INSTITUT PASTEUR DE MONTEVIDEO · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12263165

    Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

    The Board of Regents of the University of Texas System · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12257278

    Methods of treating cancer with TNF expressing myxoma virus

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12252493

    Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer

    Mirati Therapeutics, Inc. · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12247206

    Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12247973

    Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer

    UNIVERSITÄTSKLINIKUM REGENSBURG · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12233075

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Iovance Biotherapeutics, Inc. · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12233129

    Methods and compositions for the treatment of cancer

    SOUTH DAKOTA BOARD OF REGENTS · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12234516

    Biomarkers of response to HIF-2-alpha inhibition in cancer and methods for the use thereof

    The Board of Regents of the University of Texas System · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12233087

    Palladium hyaluronic acid particles and methods of managing cancer or angiogenic conditions

    The United States Government represented byt The United States Department of Veterans Affairs · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12233135

    Therapeutic constructs for treating cancer

    PRECISION MOLECULAR INC. · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12233073

    Skin care formulations and skin cancer treatment

    Regents of the University of Minnesota · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12227482

    Compounds and compositions for the treatment of cancer

    The Regents of the University of California · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12227763

    Methods and compositions for treating cancer

    CRISPR THERAPEUTICS AG · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12230364

    Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12226434

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12221627

    Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12220420

    Combination therapy for cancer treatment

    Galera Labs, LLC · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12220415

    WEE1 kinase inhibitors and methods of treating cancer using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

1,930 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.